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Purpose: Osteosarcoma is an aggressive malignant neoplasm, and conﬂicting ﬁndings have been re-
ported on the survival and function recovery in osteosarcoma patients experiencing limb salvage or
amputation. In the present study, we compared clinical outcomes regarding limb salvage surgery vs.
amputation for osteosarcoma patients by a meta-analysis.
Method: Literature search was conducted in CNKI, Medline, Embase, the Cochrane Database, and Web of
Sciences, and the quality of included studies was evaluated based on Newcastle-Ottawa scale quality
assessment. Odds ratio and 95% conﬁdence interval of the local recurrence, 5-year overall survival, and
metastasis occurrence were calculated.
Results: 17 articles were included according to selection criteria. There were 1343 patients in total de-
rived from these studies. Our result showed that there was no signiﬁcant difference between limb sal-
vage surgery and amputation with respect to local recurrence, and patients with limb salvage surgery
had a higher 5-year overall survival, and a lower metastasis occurrence.
Conclusions: The present study provided more comprehensive evidences to support limb salvage surgery
as an optimal treatment of osteosarcoma patients.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
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Osteosarcoma is an aggressive bone neoplasm arising from primi-
tive transformed cells of mesenchymal origin. It was such a fatal dis-
ease that “months to metastasis” rather than actual survival time, was
used to measure the outcomes of treatment in studies of early stage. In
the 1950s, there was no optional therapy that could signiﬁcantly in-
crease the survival rate, with a 5-year survival rate of 22% [1]. However,
with the aid of effective chemotherapeutic drugs the survival rate of
osteosarcoma has been signiﬁcantly improved since the late 1970s
[2,3]. Recently, the gold standard of osteosarcoma chemotherapy have
been based on around 5 drugs; high-dose methotrexate (HDMTX) with
leucovorin rescue, doxorubicin (adriamycin), cisplatin, ifosfamide, and
etoposide [4]. Combinations of these drugs, mostly in the form of
neoadjuvant as well as adjuvant MAP, are the current management for
osteosarcoma [5], and various chemotherapy protocols are still under
investigation. The experience with radiotherapy is limited, as osteo-
sarcoma is long considered resistant to applicable doses of radiation.
However, recent data suggest that the combined approach of irradia-
tion with chemotherapy may be useful in patients who have micro-
scopic residual tumor foci following intralesional resection [6].
With the advent of effective neoadjuvant chemotherapy in the
1970s, limb salvage surgery (LSS) has been taken as a potential
treatment for osteosarcoma [7,8]. Usually, LSS has functional and
physiological advantages over traditional amputative procedures
when combined with neoadjuvant or adjuvant chemotherapy [9]. It is
now generally accepted that LSS is indicative for localized osteo-
sarcoma, while surgical amputation is adopted for high malignancy
osteosarcoma. However, there are still some surgeons holding the
view that immediate and aggressive removal of the tumor will prevent
the progression of fracture-induced disease, and consequently ampu-
tation is considered to be a better option for osteosarcoma patients
with pathologic fracture [10–13].
Conﬂicting ﬁndings have been reported on the survival and
function recovery between treatments of LSS and amputation in
patients with osteosarcoma. Toward this end, a meta-analysis of
published clinical trials was performed to compare the clinical efﬁ-
cacy of LSS and amputation treatments in terms of local recurrence,
5-year overall survival rate, and metastatic occurrence. Several stu-
dies have attempted similar meta-analysis [14]; however, the in-
cluded studies were much smaller, and their scopes were restricted
to speciﬁc therapies compared with this meta-analysis. Through
more extensive osteosarcoma literature, this meta-analysis tries to
give a comprehensive conclusion on the outcomes in osteosarcoma
patients receiving LSS and amputation. Such information will help us
determine the most appropriate osteosarcoma-treating method.2. Material and methods
2.1. Literature search
A comprehensive and complete search of Medline, Embase,
Cochrane Database, Web of Sciences, and CNKI was performed
from June 2014 to July 2014, using the search terms: “osteo-
sarcoma”, “limb salvage” and “amputation”. There was no lan-
guage or other restrictions. All articles with raw descriptive data
were included, including original research, clinical trials, case re-
ports, databases, letters, and reviews.2.2. Included studies
Articles were included if they were (1) comparative study be-
tween LSS and amputation groups, (2) patients with osteosarcoma
in their lower limb, (3) sufﬁcient data was provide in terms of local
recurrence, 5-year overall survival rate, or occurrence of metas-
tasis. Exclusion criteria were as follows: (1) studies only reported
data related to LSS or amputation groups without a comparison,
(2) general case series with less than 20 total patients, (3) letters,
case reports, editorials or reviews.
2.3. Data extraction
Outcome data were collected from the articles by two authors
of our study. The authors used a structured sheet, and then
gathered all the data into a database. Study characteristics in-
cluded year of publication, number of patient with LSS and am-
putation, study period, gender, Enneking stage, response to che-
motherapy, follow-up, etc. Any disagreement was resolved by
continuing discussions until a consensus was reached.
2.4. Study quality
With the Newcastle–Ottawa scale (NOS) quality assessment as
recommended by the Cochrane Observational Studies Method
Working Group, the quality of included articles was evaluated by two
independent reviewers. This scale has a maximum nine points con-
cerning quality of selection, comparability, exposure, and outcome of
study participants. Because of the variable quality of the observa-
tional studies, we took the criteria of 5 or more NOS scores as studies
with good quality.
2.5. Statistical analysis
The outcome of measurement used in our study was local re-
currence, 5-year overall survival rate, and occurrence of metas-
tasis, which were all dichotomous data. We used the software of
the Cochrane Collaboration (Review Manager 5.2) to calculate OR
and 95% CI for all outcomes. Statistical heterogeneity among the
included studies was assessed by the Chi squared and I2 tests.
Statistically signiﬁcant heterogeneity was deﬁned as an I2
value40.5. A random effects model was selected for hetero-
geneous data; otherwise, a ﬁxed effect model was selected.
Funnel plots were used to test the possibility of publication
bias, which exhibited the intervention effect from the individual
study against the respective standard error. A symmetrical plot
represents no bias, and any asymmetry of the plot suggests the
existence of publication bias.
3. Results
3.1. Literature information
In the preliminary literature search, 137 potentially relevant
articles were identiﬁed. However, according to the inclusion cri-
teria, only 17 articles [15–31] were selected (Fig. 1; Table S1). All of
the 17 research articles were retrospective studies. The publication
dates ranged from 1996 to 2012. 1343 patients with osteosarcoma
were comprised totally, of whom 617 patients received LSS and
726 received amputation. The results of quality assessment by NOS
are shown in Table 1, and the detail information of patients in each
articles were listed in Table 2. Among 5 of the studies
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Table 1
Quality assessment for the 17 included articles based on Newcastle–Ottawa quality assessment scale.
Selection Comparability Exposure
Refs. Inclusion
criteria
Sample size
450
Endpoint Anatomical
location
Enneking
stage
Chemotherapy Local
recurrence
5-year overall
survival
Metastatic NOS
Abudu et al. [12] * – * * * * * * * 8*
Bacci et al. [13] * – * * * * * – – 6*
Bacci et al.b [14] * * * – – * * * * 7*
Bramer et al. [15] * * * * – * * – – 6*
Ferguson et al. [16] * – * * – * * – – 5*
Guo et al. [17] * – * * – * * – * 6*
Hegyi et al. [18] * * * – – * * * * 7*
Jiang et al. [19] * * * * * * * – – 8*
Kim et al. [20] * – * * – * * – – 5*
Ma et al. [21] * * * * – * – * – 6*
Mavrogenis et al.
[22]
* – * * – * * – * 6*
Niu et al. [23] * – * * * * * * * 8*
Robert et al. [24] * * * * – – * * – 6*
Scully et al. [25] * * * * * * * * – 8*
Xu et al. [26] * * * * * * * * – 8*
Zhang et al. [27] * – * * * * * – * 7*
Zhao et al. [28] * * * * * * * – – 7*
X. Li et al. / Journal of Bone Oncology 5 (2016) 15–21 17[20,22,25,30,31] patients with Enneking Stage-IIA, and Stage-IIB
osteosarcoma were both included. For other 5 studies
[15,16,26,28,29], patients with Enneking Stage-IIB osteosarcoma
were included. Histologic response to preoperative chemotherapy
is reported to be a independent prognostic factor of osteosarcoma
[32]. Among the included studies, 7 studies assessed the histologicresponse to preoperative chemotherapy [16,17,18,21,23,25,28].
3.2. Study heterogeneity and publication bias
The P-value for study heterogeneity was 0.26, 0.29, 0.80 for three
outcomes including local recurrence, 5-year overall survival rate, and
Table 2
Characteristic of the 17 included studies.
Ref. Abudu et al.
[12]
Bacci et al.
[13]
Bacci et al.b
[14]
Bramer et al.
[15]
Ferguson et al.
[16]
Guo et al.
[17]
Hegyi et al. [18] Jiang et al. [19] Kim et al.
[20]
Country England Italy Italy UK Canada China Hungary China Korea
Patient Number 40 46 560 56 31 21 122 64 37
LSS, 27 35 95 44 19 13 92 32 3
Amputation 13 11 465 12 12 8 30 32 4
Study period 1975–1994 1983–1999 1983–1995 1983–2003 1989–2006 1998–2008 1988–2006 2001–2011 –
Male 25 24 320 36 14 14 65 46 26
Female 14 22 240 20 17 7 57 18 11
Median age(range), years 18 (2–46) 11 (3–20) – 16 (4–57) 30 (11–8) 14.5 (9–17) 13.873.6a 18.476.3 (12–
30)
–
Enneking stage Stage-IIB Stage-IIB – – – Stage-IIA,
Stage-IIB
– Stage-IIA, Stage-
IIB
–
Follow-up(range),
months
55 (8–175) 132
(36–240)
22.6 (3–96) 117 (7–252) – 38 (28–62) – 8–42 43
(10–228)
Poor chemotherapy – 12 (26%) 194 (35%) 43 (78%) – – 67 (55%) – 23 (62%)
Local recurrence
LSS 5 1 6 6 2 2 – 2 4
Amputation 0 1 20 2 0 – – 2 0
5-year Survival
LSS 17 – 60 – – 9 58 25 –
Amputation 6 – 230 – – 3 23 19 –
Metastatic occurrence
LSS 12 – – – – 1 – – –
Amputation 9 – – – – 4 – – –
Ref. Ma et al.
[21]
Mavrogenis et al. [22] Niu et al.
[23]
Robert et al.
[24]
Scully et al. [25] Xu et al. [26] Zhang et al. [27] Zhao et al. [28]
Country China Italy China USA USA China China China
Patient Number 51 42 22 57 52 58 31 53
LSS, 32 23 12 33 30 43 17 37
Amputation 19 19 10 24 22 15 14 16
Study period 1991–1999 1985–2010 1992–2001 2007–2008 1977–1996 1992–2002 – 1996–2007
Male 35 23 15 20 28 30 26 –
Female 16 19 7 37 24 28 5 –
Median Age(range), years 22.3 (10–47)
a
26 (7–78)a 18 (3–36) 33.8 (16.1–52) 23717.4a 20.26
(12–55)
17a 19.5 (5–45)a
Enneking stage – Stage-IIA, Stage-IIB Stage-IIB – Stage-IIB Stage-IIB Stage-IIA,
Stage-IIB
Stage-IIA, Stage-
IIB
Follow-up(range), months 72 (60–144) 60 (8–288) 54.7 (8–146) 223.2
(39.6–338.4)
54 (6–152.4) 129.6
(72–192)
43.2 –
Poor chemotherapy – 7 (17%) – – 29 (64%) – – –
Local recurrence
LSS 2 5 2 – 7 7 5 3
Amputation – 2 1 – 4 1 12 ( 1
5-year Survival
LSS 12 – 8 – 19 19 6 19
Amputation 7 – 4 – 12 8) 1
Metastatic Occurrence
LSS – 1 3 – – –
Amputation – 3 6 – – –
X. Li et al. / Journal of Bone Oncology 5 (2016) 15–2118metastatic occurrence. As a result of the true difference in terms of
treatment effect, clinical characteristics, etc., the variability (I2) across
all studies was 18%, 16%, and 0% for three outcomes respectively. All
the results above indicated that there was no heterogeneity among
the included studies ( Tables 3–5). Moreover, the funnel plots for all
outcome measurements were symmetrical (Fig. 2A–C). All the spots
representing individual studies fell evenly within the top of the in-
verted funnel, indicating that there was no publication bias.3.3. Meta-analysis of local recurrence
1127 cases from 14 studies were selected for meta-analysis of
local recurrence. The overall incidence of local recurrence in LSS
and amputation group was 11.88% (57 of 480) and 7.73% (50 of
647), respectively. The results showed that there was no signiﬁcant
differences between LSS and amputation group (OR: 1.03 with 95%
CI ranging from 0.65 to 3.30; Z¼0.14, P¼0.89) (Table 3; Fig. 3).3.4. Meta-analysis of 5-year overall survival
Totally, 1074 cases from 10 studies were analyzed for 5-year overall
survival. The 5-year overall survival rate in LSS and amputation group
was 58.60% (252 of 430) and 49.84% (321 of 644), respectively. In pa-
tients treated with LSS, the 5-year overall survival rate was signiﬁcantly
higner than those treated with amputation (OR: 1.47 with 95% CI ran-
ging from 1.10 to 1.97; Z¼2.61, Po0.05) (Table 4; Fig. 4).3.5. Meta-analysis of metastasis occurrence
125 cases from 4 studies were analyzed for metastatic analysis.
The overall incidence of metastasis occurrence in LSS and ampu-
tation group was 22.67% (17 of 75) and 44% (22 of 50), respectively.
Patients treated with LSS had a signiﬁcantly lower metastasis oc-
currence compared those with amputation (OR: 0.24 with 95% CI
ranging from 0.10 to 0.60; Z¼3.05, Po0.05) (Table 5; Fig. 5).
Table 3
Statistic summary of forest plot of comparison: local recurrence of LSS vs. ampu-
tation for the treatment of osteosarcoma.
Study LSS Amputation Weight (%) Odds Ratio
Events Total Events Total M–H, Fixed, 95% CI
Abudu et al. 5 27 0 13 1.5 6.60 [0.34, 128.99]
Bacci et al. 1 35 1 11 4.2 0.29 [0.02, 5.14]
Bacci et al.b 6 95 20 465 17.9 1.50 [0.59, 3.84]
Bramer et al. 6 44 2 12 7.6 0.78 [0.14, 4.52]
Ferguson et
al.
2 19 0 12 1.5 3.57 [0.16, 81.03]
Guo et al. 2 13 5 8 14.8 0.11 [0.01, 0.87]
Jiang et al. 2 32 2 32 5.3 1.00 [0.13, 7.57]
Kim et al. 4 33 0 4 2.1 1.37 [0.06, 30.04]
Mavrogenis
et al.
5 23 2 19 4.8 2.36 [0.40, 13.84]
Niu et al. 2 12 1 10 0.0 1.80 [0.14, 23.37]
Scully et al. 7 30 4 22 10.0 1.37 [0.35, 5.41]
Xu et al. 7 43 1 15 3.5 2.72 [0.31, 24.19]
Zhang et al. 5 17 12 18 23.2 0.21 [0.05, 0.87]
Zhao et al. 3 37 1 16 3.6 1.32 [0.13, 13.79]
Total (95%) CI 57 480 50 647 100.0 1.03 [0.65, 1.64]
Heterogeneity: χ2¼14.47, df¼12 (P¼0.26); I2¼18%.
Test for over effect: Z¼0.14 (P¼0.89).
Table 4
Statistic summary of forest plot of comparison: 5-year overall survival of LSS vs.
amputation for the treatment of osteosarcoma.
Study LSS Amputation Weight (%) Odds Ratio
Events Total Events Total M–H, Fixed, 95% CI
Abudu et
al.
17 27 6 13 4.0 1.98 [0.52, 7.58]
Bacci et al.b 60 95 230 465 38.5 1.75 [1.11, 2.76]
Guo et al. 9 13 3 8 1.5 3.75 [0.59, 23.94]
Hegyi et al. 58 92 23 30 17.2 0.52 [0.20, 1.34]
Jiang et al. 25 32 19 32 5.6 2.44 [0.82, 7.31]
Ma et al. 12 32 7 19 7.4 1.03 [0.32, 3.33]
Niu et al. 8 12 4 10 1.9 3.00 [0.52, 17.16]
Scully et al. 19 30 12 22 6.8 1.44 [0.47, 4.41]
Xu et al. 19 43 8 15 8.9 0.69 [0.21, 2.25]
Zhang et al. 6 17 1 14 1.0 7.09 [0.74, 68.24]
Zhao et al. 19 37 8 16 7.3 1.06 [0.33, 3.41]
Total (95%)
CI
252 430 321 644 100.0 1.47 [ 1.10, 1.97]
Heterogeneity: χ2¼11.94, df¼10 (P¼0.29); I2¼16%.
Test for overall effect: Z¼2.61 (P¼0.009).
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With the improved efﬁcacy of chemotherapy, the number of pa-
tients with osteosarcoma who received LSS instead of amputation has
signiﬁcantly increased recent years [33–37]. Moreover, LSS beneﬁts
not only malignant primary osteosarcoma patients, but also high-
grade, localized osteosarcoma patients. However, there are substantial
studies showing that the survival rate and local recurrence between
LSS and amputation for osteosarcoma have been conﬂicting [25,38]. InTable 5
Statistic summary of forest plot of comparison: metastatic occurrence in patients receiv
Study LSS Amputatio
Events Total Events
Abudu et al. 12 27 9
Guo et al. 1 13 4
Mavrogenis et al. 1 23 3
Niu et al. 3 12 6
Total (95%) CI 17 75 22
Heterogeneity: χ2¼1.02, df¼3 (P¼0.80); I2¼0%.
Test for overall effect: Z¼3.05 (P¼0.002).this study, it was concluded that patients treated with LSS had a si-
milar local recurrence and a lower metastasis occurrence compared
with those treated with amputation, which was identical with that of
Yin [14] but with more expansive literature included in our study. In
addition, we found that 5-year overall survival rate of patients treated
with LSS was higher than those treated with amputation. Therefore,
our results provide more comprehensive evidence to support LSS for
the treatment of osteosarcoma patients.
In the meta-analysis of local recurrence of LSS vs. amputation for
the treatment of osteosarcoma, there was no signiﬁcant difference in
the two surgery methods (OR: 1.03 with 95% CI ranging from 0.65 to
3.30; Z¼0.14, P¼0.89) (Table 3; Fig. 3). In ﬁve of 17 articles, the local
recurrence rate in patients undergoing LSS was dramatically higher
than those receiving amputation [15,19,23,25,29]. The sample sizes of
these ﬁve studies were relatively small. Differently from these stu-
dies, other included studies revealed similar local recurrence rates
between the two surgery methods. Moreover, in a study of Bacci
et al. [17] with more than 500 samples investigated, local recurrence
rates were found to be similar between LSS and amputation, which
offered solid evidence to evaluate the local recurrence of LSS for the
treatment of osteosarcoma.
In this meta-analysis, the overall survival at 5 years was slightly
better in those treated by LSS than those who had amputation(OR:
1.47 with 95% CI ranging from 1.10 to 1.97; Z¼2.61, Po0.05)for
treating osteosarcoma patients. Among the included studies, only
two studies of Xu et al., Hegyi et al. [21,29] found that the am-
putation resulted in better 5-year survival. Abudu et al. [15] found
that amputation didn’t come with a prolonged overall survival,
though it provide better eradication of local tumor than LSS.
However, in another article which was not included in the meta-
analysis [39], it was indicated that LSS did not affect the survival
rate. Even through our analysis results were somewhat incon-
sistent with previous research, we still concluded that LSS had a
similar 5-year overall survival rate to that of amputation.
The metastatic occurrence rate for patients treated with LSS
was signiﬁcantly lower than those treated with amputation (OR:
0.24 with 95% CI ranging from 0.10 to 0.60; Z¼3.05, Po0.05)
(Table 5; Fig. 5), which was identical with the results of Yin et al.
[14]. However, only 4 of 17 studies reported the metastasis, in-
cluding 125 patients. Abudu [15] found that the treatment of LSS
or amputation inﬂuenced the development of metastases to some
degree, 44% in patients with LSS and 69% in patients with ampu-
tation; Niu [26] reported that metastasis happened in 25% patients
treated with LSS compared with 60% in patients treated with
amputation; in the study of Mavrogenis et al. [22], one of 23 pa-
tients receiving LSS developed metastasis while 3 of 19 patients
receiving amputation did; in another study, one of 13 patients
undergoing LSS had metastatic occurrence and 4 of 8 patients
undergoing amputation had metastatic occurrence [17]. Our ana-
lysis of metastatic occurrence was based on only four articles.
There are some important prognostic factors of osteosarcoma,
such as radical resectability of the tumor, extent of disease at di-
agnosis, initial tumor volume, and response to neoadjuvant che-
motherapy[40], which makes the comparison of the two surgery
methods complicate. Thus, additional high-quality, randomizeding LSS vs. amputation for the treatment of osteosarcoma.
n Weight (%) Odds ratio
Total M–H, Fixed, 95% CI
13 34.8 0.36 [0.09, 1.44]
8 23.6 0.08 [0.01, 0.98]
19 16.2 0.24 [0.02, 2.55]
10 25.3 0.22 [0.04, 1.37]
50 100.0 0.24 [0.10, 0.60]
)C)B)A
Fig. 2. Funnel plot of comparison. A: local recurrence of LSS vs. amputation; B: 5-year overall survival of LSS vs. amputation; C: metastatic occurrence of LSS vs. amputation.
Fig. 3. Forest plot of comparison, local recurrence of LSS vs. amputation for the
treatment of osteosarcoma.
Fig. 4. Forest plot of comparison, 5-year overall survival of LSS vs. amputation for
the treatment of osteosarcoma.
X. Li et al. / Journal of Bone Oncology 5 (2016) 15–2120controlled studies are needed to conﬁrm the conclusions.5. Conclusions
In conclusion, our meta-analysis highlighted that LSS can be safely
used in localized osteosarcoma patients with lower metastatic oc-
currence and better survival, which won’t increase the risk for local
recurrence. And our meta-analysis supported the conclusions pro-
posed by Yin et al. and provided more comprehensive evidence to
support application of LSS for the treatment of osteosarcoma patients.6. Limitation
In our study, all the articles were retrospective designed, and
most of the included studies had small sample sizes that were
subjected to systematic and random bias. The small sample sizehere was more likely to be the main reason for the failure in de-
tecting heterogeneity in articles if it did exist, as the test power of
heterogeneity was low in this situation. Moreover, the number in
some studies of events for the outcome measurement was very
low. Finally, the details of Enneking Stage and response to pre-
operative chemotherapy were missing for some studies. Therefore,
even our study represented more comprehensive evidence com-
pared with previous studies, the conclusions should be conﬁrmed
by high-quality, randomized-controlled, large-sample studies.Acknowledgments
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